API | metenkefalin

metenkefalin Report issue

Small molecule Experimental

AACT DrugBank PubChem

Active Ingredient History

NOW

Met-enkephalin, also known as metenkefalin (INN), sometimes referred to as opioid growth factor (OGF), is a naturally occurring, endogenous opioid peptide that has opioid effects of a relatively short duration. It is one of the two forms of enkephalin, the other being leu-enkephalin. The enkephalins are considered to be the primary endogenous ligands of the δ-opioid receptor, due to their high potency and selectivity for the site over the other endogenous opioids. ^Wikipedia

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecule:
metenkefalin

More Chemistry

Pharmacology

Mechanism of Action:
- Delta-type opioid receptor (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

met5-enkephalin | metenkefalin | metenkephalin

Organizations (3)

Research & Development (3)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (4)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (4)

COVID-19 (Phase 2/Phase 3)

Liver Neoplasms (Phase 1)

Multiple Sclerosis, Relapsing-Remitting (Phase 3)

Pancreatic Neoplasms (Phase 2)

Overview

Highest Phase: Phase 3
# of Trials: 4
# of Trial Organizations: 3

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue